Robert A. Gasser

Infectious Disease

6900 Georgia Ave
Washington, DC 20012

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults.

A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults.

Journal: Vaccine

Published: June 13, 2023

Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.

Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.

Journal: Diabetes, obesity & metabolism

Published: March 02, 2021

Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study.

Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study.

Journal: Intestinal research

Published: October 12, 2018

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.

Journal: Gastroenterology

Published: September 13, 2016

Incidence of Medically Attended Respiratory Syncytial Virus and Influenza Illnesses in Children 6-59 Months Old During Four Seasons.

Incidence of Medically Attended Respiratory Syncytial Virus and Influenza Illnesses in Children 6-59 Months Old During Four Seasons.

Journal: Open forum infectious diseases

Published: February 23, 2016

Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥50 years old.

Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥50 years old.

Journal: PloS one

Published: February 27, 2014

Medically attended respiratory syncytial virus infections in adults aged ≥ 50 years: clinical characteristics and outcomes.

Medically attended respiratory syncytial virus infections in adults aged ≥ 50 years: clinical characteristics and outcomes.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: November 23, 2013

Translational sciences approach to RSV vaccine development.

Translational sciences approach to RSV vaccine development.

Journal: Expert review of vaccines

Published: September 24, 2013

Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein.

Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein.

Journal: Clinical and vaccine immunology : CVI

Published: December 15, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026